“A study from WorldCare Consortium® member Mayo Clinic found that men may be misdiagnosed more often than women for Alzheimer’s disease. A second study at St. Michael’s Hospital in Toronto, Canada, revealed that “even with all the latest diagnostic methods, the discrepancy between the clinical diagnosis of Alzheimer’s disease and the pathological diagnosis is about 20 percent,” according to senior research adjunct scientist Dr. David Munoz.”
20% misdiagnosis!
I consider misdiagnosis the most obvious counter point to the results of the small P2a study. Yet we have many preclinical indications and anecdotes that the drug has effects.
This is why I find genome biomarker findings so intriguing to learn about. Anavex needs to show in a next to irrefutably clear manner that it was indeed drug action that caused the strong responders to become better.
If the AAIC presentations do not do that, the share price will again suffer.
News 
Market Data 
Discover 
AI
